Mp08-04 Reliability and Preliminary Validation of a Body Image Scale Survey Instrument for Use in Bladder Cancer Patients

You have accessJournal of UrologyBladder Cancer: Epidemiology & Evaluation I (MP08)1 May 2024MP08-04 RELIABILITY AND PRELIMINARY VALIDATION OF A BODY IMAGE SCALE SURVEY INSTRUMENT FOR USE IN BLADDER CANCER PATIENTS Ava Saidian, Margaret F. Meagher, Kit Yuen, Dhruv Pruri, Tyler Stewart, and Amirali Salmasi Ava SaidianAva Saidian , Margaret F. MeagherMargaret F. Meagher , Kit YuenKit Yuen , Dhruv PruriDhruv Pruri , Tyler StewartTyler Stewart , and Amirali SalmasiAmirali Salmasi View All Author Informationhttps://doi.org/10.1097/01.JU.0001008780.87855.57.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Therapy for bladder cancer carries potentially disfiguring and permanent effects, with urinary diversion surgery carrying cosmetic and functional changes that affect body image and quality of life. However, current HRQOL surveys validated for use in bladder cancer patients have no dedicated domain measuring "body image." We sought to validate the previously developed, ten-item Body Image Scale (BIS) for use in bladder cancer patients. The BIS is scored on a 4-point Likert scale (maximum total score of 30), with higher scores representing more distress. METHODS: Native English or Spanish speaking patients who had undergone radical cystectomy and urinary diversion within the past 5 years for muscle-invasive bladder cancer were identified by the study team through an EPIC electronic medical records system search. The study sample included subjects>18 years of age and was not limited by gender, disease stage or previous treatments. Surveys were scored and analyzed for reliability and validity. RESULTS: 32 patients were identified (22 men, 10 women, 25 ileal conduits, 7 neobladders). Cronbach's alpha reliability coefficient measuring internal consistency for the BIS instrument in this group was 0.926. No item had a value less than 0.903 and item alphas ranged between 0.900 and 0.926. EORTC guidelines for scale development recommend response prevalence (the frequency of scores >0 in any item) be >30%. All ten items met the response criteria (score of >0 by >30% respondents) in our study population. A Mann-Whitney U test was run to determine if there were differences in BIS score between patients with ileal conduits and those with neobladders. Though the ileal conduit group mean (17.4), and median (16) scores were lower than the neobladder (mean=19.1 and median=22), there was no statistically significant difference in BIS scores between the two cohorts (p=0.755). CONCLUSIONS: We present a validation study for use of BIS in bladder cancer patients. This instrument can be utilized in future bladder cancer clinical trials or psycho-oncology research. Source of Funding: N/A © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e115 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Ava Saidian More articles by this author Margaret F. Meagher More articles by this author Kit Yuen More articles by this author Dhruv Pruri More articles by this author Tyler Stewart More articles by this author Amirali Salmasi More articles by this author Expand All Advertisement PDF downloadLoading ...